PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30906561-0 2019 Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. Nicotine 0-8 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 42-48 30906561-2 2019 CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotine-related behaviors because of reported CYP2B6 mRNA expression in human brain tissue. Nicotine 41-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 30906561-2 2019 CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has been proposed as relevant to nicotine-related behaviors because of reported CYP2B6 mRNA expression in human brain tissue. Nicotine 110-118 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 157-163 30906561-3 2019 Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. Nicotine 81-89 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-38 30906561-3 2019 Therefore, we hypothesized that CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. Nicotine 110-118 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-139 30906561-4 2019 We generated recombinant enzymes in insect cells corresponding to nine common CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine oxidation to nicotine iminium ion and nornicotine for both (S) and (R)-nicotine. Nicotine 150-158 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 30906561-4 2019 We generated recombinant enzymes in insect cells corresponding to nine common CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine oxidation to nicotine iminium ion and nornicotine for both (S) and (R)-nicotine. Nicotine 172-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 30906561-4 2019 We generated recombinant enzymes in insect cells corresponding to nine common CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine oxidation to nicotine iminium ion and nornicotine for both (S) and (R)-nicotine. Nicotine 172-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 30906561-9 2019 We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. Nicotine 36-44 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 30906561-9 2019 We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. Nicotine 100-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 17-23 30906561-9 2019 We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. Nicotine 100-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 30906561-9 2019 We conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6 activity in human brain. Nicotine 100-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 25652250-0 2015 Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Nicotine 42-50 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-21 27750412-6 2017 Genome-wide association studies in humans have been rapidly advanced; however, unique whole-gene deletion of P450 2A6 was subsequently developed to cover nicotine-related lung cancer risk study. Nicotine 154-162 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 109-113 25652250-0 2015 Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Nicotine 62-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-21 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 21-29 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-5 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 21-29 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-101 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 125-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-5 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 125-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-101 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 125-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-5 25652250-3 2015 CYP2B can metabolize nicotine, the main psychoactive ingredient in cigarettes; if altered brain CYP2B activity can influence nicotine brain levels, it could influence nicotine-mediated behaviors. Nicotine 125-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-101 25652250-10 2015 Together these data demonstrate that the brain CYP2B activity can influence nicotine brain levels and subsequent behaviors independent of hepatic metabolism. Nicotine 76-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-52 25652250-11 2015 This suggests that human smokers with variable CYP2B brain levels could have different nicotine levels and reinforcement, which might have a role in smoking behaviors and dependence. Nicotine 87-95 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-52 23639433-0 2013 Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. Nicotine 32-40 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 24260284-0 2013 CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. Nicotine 135-143 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 24260284-1 2013 The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Nicotine 78-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-23 24260284-1 2013 The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Nicotine 78-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 25-31 24260284-2 2013 Using CYP2A6 genotype as a covariate, we find that a non-coding polymorphism in CYP2B6 previously associated with smoking cessation (rs8109525) is also significantly associated with nicotine metabolism. Nicotine 182-190 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-86 25409894-0 2015 Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo. Nicotine 135-143 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 25409894-6 2015 The ability of CYP2B6 to metabolize nicotine was then examined, both in vitro and in vivo. Nicotine 36-44 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 25409894-9 2015 Thus, the transgenic CYP2B6 was inducible and functional, and, in the absence of mouse CYP2A and CYP2B enzymes, it contributed to nicotine metabolism in vivo. Nicotine 130-138 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 25489907-0 2015 CYP2B6 gene single-nucleotide polymorphisms in an Italian population sample and relationship with nicotine dependence. Nicotine 98-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 25489907-1 2015 The extensively polymorphic CYP2B6 gene metabolizes endogenous and exogenous compounds, among which are nicotine and bupropion, although its contribution to the systemic metabolism of nicotine still remains controversial. Nicotine 104-112 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 25489907-1 2015 The extensively polymorphic CYP2B6 gene metabolizes endogenous and exogenous compounds, among which are nicotine and bupropion, although its contribution to the systemic metabolism of nicotine still remains controversial. Nicotine 184-192 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 25489907-4 2015 The reduced activity of the CYP2B6*6 variant was significantly (p=0.025) distributed among the nicotine-dependent individuals compared to non-nicotine dependents. Nicotine 95-103 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 25489907-4 2015 The reduced activity of the CYP2B6*6 variant was significantly (p=0.025) distributed among the nicotine-dependent individuals compared to non-nicotine dependents. Nicotine 142-150 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 25489907-5 2015 Also, the CYP2B6*1/*6 genotype achieved statistical significance (p=0.016) within the nicotine-dependent individuals. Nicotine 86-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 10-16 25489907-6 2015 The high occurrence of CYP2B6*6 carriers among nicotine-dependent individuals may suggest a possible involvement in nicotine dependence, with a potential impact on smoking cessation treatments tailored to the individual smoker"s genotype. Nicotine 47-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 25489907-6 2015 The high occurrence of CYP2B6*6 carriers among nicotine-dependent individuals may suggest a possible involvement in nicotine dependence, with a potential impact on smoking cessation treatments tailored to the individual smoker"s genotype. Nicotine 116-124 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 25655887-2 2015 Nicotine, the major psychoactive compound in cigarette smoke, is metabolized by a number of enzymes, including CYP2A6, CYP2B6, FMOs, and UGTs, among others. Nicotine 0-8 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 23639433-3 2013 The objective of this study was to determine the effects of ethanol self-administration and nicotine treatment, alone and in combination, on brain CYP2B6 and CYP2E1 levels in monkeys. Nicotine 92-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 147-153 23639433-6 2013 Immunocytochemistry revealed induction of both CYP2B6 and CYP2E1 protein in certain brain regions and cells within monkey brain as a result of ethanol self-administration, nicotine treatment and combined exposure to both drugs. Nicotine 172-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 23639433-8 2013 Combined ethanol and nicotine exposure induced CYP2B6 in the caudate, putamen, thalamus and cerebellum (1.4-2.4 fold, P < 0.05), and CYP2E1 in the frontal cortex and putamen (1.5-1.8, P < 0.05). Nicotine 21-29 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 23639433-10 2013 In summary, ethanol and nicotine can induce CYP2B6 and CYP2E1 protein in the primate brain, which could potentially result in altered sensitivity to centrally acting drugs and toxins. Nicotine 24-32 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 44-50 23591849-1 2013 We explored the contribution of nitrosamine metabolism to lung cancer in a pilot investigation of genetic variation in CYP2B6, a high-affinity enzymatic activator of tobacco-specific nitrosamines with a negligible role in nicotine metabolism. Nicotine 222-230 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 22569203-0 2012 CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Nicotine 61-69 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-17 22569203-2 2012 Variations in the CYP2A6 and CYP2B6 genes, encoding enzymes responsible for nicotine metabolic inactivation and procarcinogen activation, have not been characterized in AN and may contribute toward the increased risk. Nicotine 76-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 29-35 22569203-6 2012 Nicotine metabolism [as measured by the plasma and urinary ratio of metabolites trans-3"-hydroxycotinine to cotinine (3HC/COT)] was significantly associated with CYP2A6 (P<0.001), but not CYP2B6 genotype (P=0.95) when controlling for known covariates. Nicotine 0-8 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 191-197 12439223-2 2002 The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. Nicotine 62-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 20307138-7 2010 A weak correlation between CYP2B6 and nicotine C-oxidation activity was observed, which was abrogated when controlling for CYP2A6 protein levels. Nicotine 38-46 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 16309716-0 2006 CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Nicotine 76-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 16309716-1 2006 CYP2B6 is a drug-metabolizing enzyme expressed in human tissues that can activate bupropion (a smoking cessation drug) and tobacco smoke nitrosamines and can inactivate drugs such as nicotine. Nicotine 183-191 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 16309716-3 2006 We investigated the basal expression and the effect of chronic nicotine treatment on CYP2B6 protein in African Green monkey (Cercopithecus aethiops) brain. Nicotine 63-71 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 85-91 16309716-7 2006 Chronic nicotine treatment induced CYP2B6 expression in specific cells such as astrocytes and neurons in the frontal cortex, caudate, thalamus and hippocampus. Nicotine 8-16 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 35-41 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Nicotine 103-111 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Nicotine 103-111 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 161-167 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Nicotine 201-209 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Nicotine 201-209 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 161-167 16135656-11 2005 These results as well as the inhibition analyses suggested that CYP2A6 and CYP2B6 would significantly contribute to the nicotine N-demethylation at low and high substrate concentrations, respectively. Nicotine 120-128 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 21266057-6 2011 Participants responded to survey items and provided blood samples for evaluation of phenotype and genotype of CYP2A6 and CYP2B6 enzymes involved in nicotine and bupropion metabolism. Nicotine 148-156 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 121-127 16135656-0 2005 CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Nicotine 37-45 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-17 16135656-10 2005 The nicotine N-demethylase activity at 100 microM nicotine was significantly correlated with the CYP2B6 contents (r = 0.677, p < 0.05) and S-mephenytoin N-demethylase activities (r = 0.740, p < 0.005). Nicotine 4-12 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 97-103 15364541-9 2004 Nicotine, the psychoactive and addictive chemical in cigarettes, and a known inducer of brain CYP2B6, was an efficacious activator of PXR and inducer of CYP3A4 transcription. Nicotine 0-8 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-100 12814665-1 2003 CYP2B6 metabolizes drugs such as nicotine and bupropion, and many toxins and carcinogens. Nicotine 33-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 12814665-2 2003 Nicotine induces CYP2B1 in rat brain and in humans polymorphic variation in CYP2B6 affects smoking cessation rates. Nicotine 0-8 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 76-82 12814665-9 2003 Higher brain CYP2B6 activity in smokers and alcoholics may cause altered sensitivity to centrally acting drugs, increased susceptibility to neurotoxins and carcinogenic xenobiotics and contribute to central tolerance to nicotine. Nicotine 220-228 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 1680658-0 1991 Metabolism of nicotine by rat liver cytochromes P-450. Nicotine 14-22 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 48-53 10350185-0 1999 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Nicotine 30-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 10350185-6 1999 Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 microM nicotine. Nicotine 151-159 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 10350185-6 1999 Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 microM nicotine. Nicotine 223-231 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 1680658-3 1991 The cytochromes P-450 have long been implicated in the first step in the conversion of nicotine to nicotine delta 1"(5")-iminium ion. Nicotine 87-95 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-21 1680658-5 1991 A constitutive form of P-450 is also implicated in nicotine metabolism, while purified P-450IA1 and P-450IIC6 show no detectable activity. Nicotine 51-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-28 1680658-8 1991 Our results support the notion that nicotine metabolism to cotinine by P-450 enzymes is highly species dependent. Nicotine 36-44 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 71-76 1680658-9 1991 Thus, it is unwise in some cases to extrapolate results obtained by animal model study to the possible role of specific forms of the P-450 enzymes in nicotine metabolism in humans. Nicotine 150-158 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 133-138 33329709-0 2020 Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. Nicotine 112-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 102-108 34165800-3 2021 Candidate gene studies of smoking phenotypes have identified several pharmacogenes implicated in nicotine"s pharmacokinetics (CYP2A6, CYP2B6, CYP2A13, FMOs, UGTs, and OCT2), and nicotine"s pharmacodynamic response in the central nervous system (nicotinic acetylcholine receptors, as well as through the dopaminergic and serotonergic systems). Nicotine 97-105 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 134-140